Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 2/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | BHMT | Q93088 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | GMNN | O75496 | 1/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | BLM | P54132 | 1/20 | 0.43 |
| ▸ | MVD | P53602 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | MMP12 | P39900 | 1/20 | 0.36 |
| ▸ | MMP13 | P45452 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4200738 | 0.82 | TSHR (0.50) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| Danosteine SCHEMBL1578704 | 0.79 | HSD17B10 (0.72) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| SCHEMBL1648168 | 0.79 | ALDH1A1 (0.37) | HSD17B10LMNAKMT2ATDP1ALDH1A1 | |
| SCHEMBL9573997 | 0.77 | CYP2D6 (0.67) | CYP2D6HIF1AHSD17B10BHMTMAPT | |
| Danosteine SCHEMBL11664539 | 0.77 | HSD17B10 (0.68) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| SCHEMBL8546872 | 0.77 | MAPT (0.41) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| SCHEMBL1313188 | 0.76 | CYP2D6 (0.73) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| SCHEMBL6998791 | 0.74 | TSHR (0.46) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| SCHEMBL10707714 | 0.73 | CYP2D6 (0.69) | CYP2D6HIF1AHSD17B10LMNAKMT2A | |
| Hydrochloric Acid SCHEMBL11144119 | 0.73 | CYP2D6 (0.69) | CYP2D6HIF1AHSD17B10LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8491929-B2 | Bioadhesive polymers | VAUNNEX INC. (US) | 2013-07-23 | — | — | US | disclosed |
| US-20110086095-A1 | Bioadhesive Polymers | Spherics, Inc (MA) | 2011-04-14 | — | — | US | disclosed |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2010-12-16 | — | — | US | disclosed |
| EP-2063867-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | Combinatorx, Incorporated (US) | 2009-06-03 | — | — | EP | disclosed |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-12-04 | — | — | US | disclosed |
| WO-2008079404-A2 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | COMBINATORX, INCORPORATED (US) | 2008-07-03 | — | — | WO | disclosed |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2008-06-05 | — | — | US | disclosed |
| EP-1901720-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | Spherics, Inc. (US) | 2008-03-26 | — | — | EP | disclosed |
| WO-2008002471-A2 | EROSION-STABILIZED BIOADHESIVE POLYMERS FUNCTIONALIZED OR BLENDED WITH CATECHOL AND DERIVATIVES THEREOF | SPHERICS, INC. (US) | 2008-01-03 | — | — | WO | disclosed |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-06-28 | — | — | US | disclosed |
| WO-2007002516-A2 | IMPROVED DOSAGE FORMS FOR MOVEMENT DISORDER TREATMENT | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002318-A2 | BIOADHESIVE POLYMERS | SPHERICS, INC. (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | SPHERICS, INC. (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110086095-A1 | Bioadhesive Polymers | CD44, EPCAM, ABCG2 | CYP2D6 195/4885HIF1A 323/4885HSD17B10 1542/4885 |
| US-20100316712-A1 | PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF PARKINSON'S DISEASE AND RELATED DISORDERS | PARK7, SNCA, COMT | CYP2D6 188/4885HIF1A 3829/4885HSD17B10 2155/4885 |
| US-20070148238-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | CYP2D6 16/4885HIF1A 4466/4885HSD17B10 605/4885 |
| US-20080131492-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | CYP2D6 16/4885HIF1A 4466/4885HSD17B10 605/4885 |
| US-20070003621-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | CYP2D6 16/4885HIF1A 4466/4885HSD17B10 605/4885 |
| US-20080299204-A1 | Dosage forms for movement disorder treatment | PARK7, SNCA, HTT | CYP2D6 16/4885HIF1A 4466/4885HSD17B10 605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.